1. Home
  2. IIIV vs REPL Comparison

IIIV vs REPL Comparison

Compare IIIV & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo i3 Verticals Inc.

IIIV

i3 Verticals Inc.

HOLD

Current Price

$20.04

Market Cap

434.2M

Sector

Technology

ML Signal

HOLD

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$10.08

Market Cap

407.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IIIV
REPL
Founded
2012
2015
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
434.2M
407.1M
IPO Year
2018
2018

Fundamental Metrics

Financial Performance
Metric
IIIV
REPL
Price
$20.04
$10.08
Analyst Decision
Strong Buy
Hold
Analyst Count
5
9
Target Price
$33.20
$5.67
AVG Volume (30 Days)
409.0K
5.4M
Earning Date
05-07-2026
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.25
EPS
0.08
N/A
Revenue
N/A
N/A
Revenue This Year
$9.05
N/A
Revenue Next Year
$8.07
N/A
P/E Ratio
$247.56
N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.47
$1.50
52 Week High
$33.97
$13.24

Technical Indicators

Market Signals
Indicator
IIIV
REPL
Relative Strength Index (RSI) 46.45 70.76
Support Level $18.82 $8.25
Resistance Level $23.62 $10.71
Average True Range (ATR) 0.93 0.88
MACD 0.06 0.02
Stochastic Oscillator 30.73 74.33

Price Performance

Historical Comparison
IIIV
REPL

About IIIV i3 Verticals Inc.

i3 Verticals Inc provides mission-critical enterprise software solutions to public sector entities. These comprehensive cloud-native solutions address a broad range of government functions, including courts and public safety, public administration, utilities, transportation and schools. The company generates the majority of revenue from software and related services, including the sale of subscriptions, recurring services, ongoing support, licenses, and installation and implementation services specific to software.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Share on Social Networks: